Friday, November 30, 2018

Triple combination cancer immunotherapy improves outcomes in preclinical melanoma model

In adoptive cell transfer immunotherapy, T cells able to recognize a tumor are harvested, expanded in the laboratory, and then reintroduced to attack the tumor. However, they often do not persist long enough to finish the job. A triple combination regimen of adoptive T cell transfer, a PIM kinase inhibitor, and a PD1 inhibitor improved T cell persistence and tumor control in a mouse model of melanoma, report investigators.

from Top Health News -- ScienceDaily https://ift.tt/2P9EC9h

No comments:

Post a Comment

They fled the flames—now jaguars rule a wetland refuge

After devastating wildfires scorched the Brazilian Pantanal, an unexpected phenomenon unfolded—more jaguars began arriving at a remote wetla...